ABVC BIOPHARMA, INC.
Close on Oct 19, 2026
- Market cap
- $23.71M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Quarterly results announced on Form 8-K, Item 2.02
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q4 FY2025 Ended Dec 31, 2025 | Mar 3, 2026 | During market hours | – | – | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 3, 2025 | Before market open | $1.28M | – | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 14, 2025 | Before market open | – | $-0.13 | – |
| Q1 FY2025 Ended Mar 31, 2025 | Apr 15, 2025 | During market hours | – | – | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 14, 2024 | Before market open | $389.28K | $-0.02 | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 15, 2024 | Before market open | $117.14K | $-0.09 | – |
| Q4 FY2023 Ended Dec 31, 2023 | Mar 14, 2024 | Before market open | – | – | – |
| Q3 FY2023 Ended Sep 30, 2023 | Nov 15, 2023 | Before market open | $15.88K | $-0.82 | – |
| Q2 FY2023 Ended Jun 30, 2023 | Jul 24, 2023 | Before market open | – | – | – |
| Q1 FY2023 Ended Mar 31, 2023 | Apr 3, 2023 | During market hours | – | – | – |
| Q4 FY2022 Ended Dec 31, 2022 | Mar 31, 2023 | During market hours | – | – | – |
| Q4 FY2021 Ended Dec 31, 2021 | Mar 31, 2022 | During market hours | – | – | – |
Press releases
Announcements Abvc Biopharma filed with the SEC
ABVC BioPharma Reports 2025 Form 10-K
Results of operations · Prior financials no longer reliable · EX-99.1 to Form 8-K
ABVC BioPharma Reports 230% YoY Licensing Revenue Growth and 181%
Results of operations · EX-99.1 to Form 8-K
ABVC BioPharma, Inc. Reports 103% Year-Over-Year
Results of operations · EX-99.1 to Form 8-K
ABVC BioPharma Regains Nasdaq Minimum Bid Price
Listing notice · Regulation FD disclosure · EX-99.1 to Form 8-K/A
ABVC BioPharma Announces First Quarter 2025
Results of operations · EX-99.1 to Form 8-K
ABVC BioPharma Announces 2024 Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K/A
ABVC BioPharma Announces 2024 Financial Results
Results of operations · Prior financials no longer reliable · Regulation FD disclosure · EX-99.1 to Form 8-K
ABVC BioPharma, Inc. Granted Additional 180-Day
Listing notice · Regulation FD disclosure · EX-99.1 to Form 8-K/A
ABVC BioPharma Inc. Reports Q3 2024 Financial
Results of operations · EX-99.1 to Form 8-K
Corporate Overview NASDAQ: ABVC 2024
Regulation FD disclosure · EX-99.1 to Form 8-K
ABVC BioPharma Inc. Reports Strong Q2 2024 Financial
Results of operations · EX-99.1 to Form 8-K
BioPharma Reports Annual 2023 Financials and Provides Fiscal Year 2024 First Quarter Business Update
Results of operations · EX-99.1 to Form 8-K
ABVC Acquires $2.96 Million Worth of Land
Material agreement · Unregistered share sale · Other events · EX-99.1 to Form 8-K
ABVC BioPharma Reports Third Quarter 2023 Financial
Results of operations · EX-99.1 to Form 8-K
PRESS RELEASE, DATED AUGUST 7, 2023
Other events · EX-99.1 to Form 8-K
PRESS RELEASE, DATED JULY 21, 2023
Results of operations · Charter or bylaw amendment · Other events · EX-99.1 to Form 8-K
Cor p orate Overview N A SD A Q: ABVC 2023
Regulation FD disclosure · EX-99.1 to Form 8-K
ABVC BioPharma Announces Fiscal Year 2022 Financial
Results of operations · Other events · EX-99.1 to Form 8-K/A
ABVC BioPharma Announces Fiscal Year 2022 Financial
Results of operations · Other events · EX-99.1 to Form 8-K
ABVC BioPharma Receives $3.175 Million Investment
Material agreement · Unregistered share sale · Other events · EX-99.1 to Form 8-K
PRESS RELEASE, DATED SEPTEMBER 13, 2022
Other events · EX-99.1 to Form 8-K
SHAREHOLDER LETTER, DATED SEPTEMBER 12, 2022
Other events · EX-99.2 to Form 8-K
PRESS RELEASE DATED JUNE 21, 2022
Material agreement · Other events · EX-99.1 to Form 8-K
Old Warm Springs Blvd., Fremont, CA 94538
Regulation FD disclosure · EX-99.1 to Form 8-K
NOTICE OF ANNUAL MEETING OF STOCKHOLDERS
Regulation FD disclosure · EX-99.2 to Form 8-K
PRESS RELEASE DATED MARCH 31, 2022
Results of operations · EX-99.1 to Form 8-K